Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 January 2024 | Story Leonie Bolleurs | Photo Supplied
Zola Valashiya
Nearly a decade ago, Zola Valashiya completed his LLB at UFS and is currently working towards his second LLM in Technology and Innovation at the Seattle University School of Law.

Zola Valashiya graduated from the UFS almost ten years ago with an LLB. Since then, amid life’s twists and turns, he obtained an LLM from the University of Washington, secured a job with a successful law firm in the US, and married the love of his life. Currently, Zola is pursuing a second LLM in Technology and Innovation with the Seattle University School of Law.

Following the advice of a dear friend, Zola figured out what drives him and pursued it relentlessly. “This very simple piece of advice taught me the value of my time, and how much power you take back when you prioritise and protect it,” he remarks.

Advancing the greater good

Fast forward nine-plus years since UFS graduation day, Zola works as a strategic adviser at Coopersmith Law + Strategy, a boutique firm in Seattle specialising in health care, global health, gender/racial equality, and climate health.

“The legal work I do involves various tasks, from drafting legal contracts to conducting data analysis, and developing business strategies for deploying new technologies in health systems or addressing climate change. I value this environment because our efforts are focused on advancing the greater good. I have the opportunity to work on projects that I know will benefit individuals, communities, and the planet,” says Zola.

One of the highlights of his career occurred during the pandemic when he played a key role in preserving one of the largest US training programmes for physicians from diverse backgrounds who serve marginalised communities.

He explains, “The pandemic placed a strain on health-care systems worldwide, leading to cost-cutting measures in private hospitals, the termination of community health programmes, and the closure of small clinics in remote areas, in order to recover from the financial losses. However, these programmes and clinics are vital to the communities they serve because the nurses and doctors are often the only health-care providers for miles around. My contributions have helped to ensure the programme’s continuation, and the continued delivery of quality health care to underserved communities.”

Diversifying his skill set

For the future, Zola says he is working towards diversifying his skill set. “The modern-day lawyer needs to know more than just the law. I have learned coding skills, and I am currently focused on expanding my knowledge of artificial intelligence. In so doing, I am equipping myself with the necessary tools and expertise to thrive in this rapidly evolving field, thereby future-proofing my career.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept